• Odd Twist in Phase 3 Alzheimer's Trial for Novel Tau Inhibitor

    2 monthes ago - By Medscape

    Although the novel tau aggregation inhibitor hydromethylthionine mesylate did not reach its coprimary endpoints, investigators insist there's more to the story ― especially with the control agent used.
    Medscape Medical News
    Read more ...